BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38554419)

  • 1. Comparing Safety and Efficacy of TACE + Apatinib in Combination with a PD-1 Inhibitor versus a Non-triple Therapy for Treating Advanced Primary Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    Pan D; Liu H; Qu P; Chen X; Ma X; Wang Y; Qin X; Han Z
    J Gastrointestin Liver Dis; 2024 Mar; 33(1):85-93. PubMed ID: 38554419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Li D; Zhang C; Yang K; Ma Z; Ma L; Cheng C; Xu L; Wan S
    Medicine (Baltimore); 2024 Jan; 103(3):e36865. PubMed ID: 38241568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of transcatheter arterial chemoembolization combined with either
    Li Y; Li H; Hu H; Yuan H; Zhao Y
    J Cancer Res Ther; 2020; 16(7):1691-1697. PubMed ID: 33565518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis.
    Gong A; Li X
    World J Surg Oncol; 2022 Mar; 20(1):69. PubMed ID: 35246145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
    Yang Z; Chen G; Cui Y; Xiao G; Su T; Yu J; Zhang Z; Han Y; Yang K; Jin L
    Cancer Biol Ther; 2019; 20(3):321-327. PubMed ID: 30332553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma.
    Chen S; Yu W; Zhang K; Liu W
    BMC Cancer; 2018 Nov; 18(1):1131. PubMed ID: 30453925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis.
    Shen L; Chen S; Qiu Z; Qi H; Yuan H; Cao F; Xie L; Chen Q; Li W; Fan W
    J Cancer Res Ther; 2020 Sep; 16(5):1063-1068. PubMed ID: 33004748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study.
    Duan X; Li H; Kuang D; Chen P; Zhang K; Li Y; He X; Xing C; Wang H; Liu Y; Xie L; Zhang S; Zhang Q; Zhu P; Dong H; Xie J; Li H; Wang Y; Shi M; Jiang G; Xu Y; Zhou S; Shang C; Ren J; Han X
    Hepatol Int; 2023 Aug; 17(4):915-926. PubMed ID: 37012542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: a systematic review and meta-analysis.
    Zhao S; Zhang T; Dou W; Wang E; Wang M; Wang C; Du X; Liu L
    Ann Transl Med; 2020 Apr; 8(8):542. PubMed ID: 32411765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study.
    Wang H; Liu D; Wang C; Yu S; Jin G; Wang C; Zhang B; Zhang D; Shao D
    Clin Res Hepatol Gastroenterol; 2022; 46(6):101869. PubMed ID: 35108656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study.
    Yin L; Liu KC; Lv WF; Lu D; Tan YL; Wang GX; Dai JY; Zhu XH; Jiang B
    Cancer Imaging; 2023 May; 23(1):52. PubMed ID: 37254146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Efficacy Among Transcatheter Arterial Chemoembolization (TACE)-Radiofrequency Ablation Plus Apatinib, TACE Plus Apatinib, and TACE Alone for Hepatocellular Carcinoma: A Retrospective Study.
    Ouyang T; Cao Y; Chen L; Zheng C
    Cardiovasc Intervent Radiol; 2022 Jun; 45(6):780-790. PubMed ID: 35410405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of TACE + Lenvatinib in Treating Advanced Hepatocellular Carcinoma: A Systematic Review and Meta- analysis.
    Pan D; Liu H; Ma X; Qu P; Cao M; Qin X; Tang J; Pan R; Huang Q; Han Z
    J Gastrointestin Liver Dis; 2023 Jun; 32(2):222-229. PubMed ID: 37345593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma.
    Liu J; Xie S; Duan X; Chen J; Zhou X; Li Y; Li Z; Han X
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):69-76. PubMed ID: 31813003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
    Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
    BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of TACE combined with Apatinib in the treatment of advanced hepatocellular carcinoma.
    Zhu Y; Feng B; Mei L; Sun R; Guo C; Zhu J
    J BUON; 2019; 24(2):608-614. PubMed ID: 31128013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial.
    Lu W; Jin XL; Yang C; Du P; Jiang FQ; Ma JP; Yang J; Xie P; Zhang Z
    Cancer Biol Ther; 2017 Jun; 18(6):433-438. PubMed ID: 28548587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sorafenib combined with TACE in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
    Li D; Pang Y; Xu L; Xu X
    J BUON; 2021; 26(4):1355-1364. PubMed ID: 34564992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.
    Jin ZC; Zhong BY; Chen JJ; Zhu HD; Sun JH; Yin GW; Ge NJ; Luo B; Ding WB; Li WH; Chen L; Wang YQ; Zhu XL; Yang WZ; Li HL; Teng GJ;
    Eur Radiol; 2023 Dec; 33(12):8669-8681. PubMed ID: 37368105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.
    Shuanggang C; Shen L; Qiu Z; Qi H; Cao F; Xie L; Fan W
    J Cancer Res Ther; 2020; 16(2):250-257. PubMed ID: 32474509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.